Trial record 7 of 15 for:    Open Studies | "Cholera"

A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by PaxVax, Inc.
Information provided by (Responsible Party):
PaxVax, Inc. Identifier:
First received: March 25, 2014
Last updated: July 10, 2014
Last verified: July 2014

Demonstrate that the vaccine offers protection based on antibody levels in older adults and is similar to antibody levels in adults aged 18-45 following vaccination with PXVX0200.

Condition Intervention Phase
Biological: PXVX0200
Biological: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase III Randomized, Double-blind, Placebo-controlled Study in Older Adults to Assess Immunogenicity and Clinical Acceptability of a Single-dose of the Live Oral Cholera Vaccine Candidate PXVX0200 Vibrio Cholerae O1 Serotype Inaba Vaccine Strain CVD 103-HgR

Resource links provided by NLM:

Further study details as provided by PaxVax, Inc.:

Primary Outcome Measures:
  • Seroconversion by vibriocidal antibody (i.e., a 4-fold rise over baseline titer) [ Time Frame: up to 28 days following vaccination ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percentage of vaccinees with at least a 4-fold rise vibriocidal antibody [ Time Frame: up to 180 days after vaccination ] [ Designated as safety issue: No ]
  • number of subjects with serious and non serious adverse events [ Time Frame: following vaccination through 180 days ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 400
Study Start Date: May 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PXVX0200
PXVX0200 Single dose; liquid suspension after reconstitution with buffer; > 2x108 CFU in a liquid suspension
Biological: PXVX0200
Placebo Comparator: Placebo
Placebo physiological saline
Biological: Placebo


Ages Eligible for Study:   46 Years to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy men or women,
  • age 46 to 64 years inclusive;
  • normal medical history and physical examination
  • Women must have a negative pregnancy test

Exclusion Criteria:

  • travel to a cholera endemic area in the previous 5 years;

    • abnormal stool pattern or regular use of laxatives;
    • Currently active unstable or undiagnosed medical conditions
    • current or recent antibiotic use;
    • pregnancy or nursing;
    • Previously received a licensed or investigational cholera vaccine
    • History of cholera or enterotoxigenic E. coli infection
    • History of Guillain-Barré Syndrome
    • Received or plans to receive any other licensed vaccines, except for seasonal influenza
    • Recipient of bone marrow or solid organ transplant
    • Malignancy (excluding non-melanotic skin cancers) or lymphoproliferative disorders diagnosed or treated during the past 5 years
    • Use of systemic chemotherapy in the previous 5 years prior to the study
    • any immunosuppressive medical condition
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02100631

United States, Alabama
Coastal Clinical Research Recruiting
Mobile, Alabama, United States, 36608
Contact: Harry Studdard, MD    251-414-1984      
Principal Investigator: Harry Studdard, MD         
United States, Florida
Avail Clinical Recruiting
Deland, Florida, United States, 32720
Contact: John Hill, MD    386-785-2183      
Principal Investigator: John Hill, MD         
Miami Research Associates Recruiting
Miami, Florida, United States, 33143
Contact: Robert Feldman, MD    305-667-4511      
Principal Investigator: Robert Feldman, MD         
Palm Beach Research Center Recruiting
Palm Beach, Florida, United States, 33409
Contact: Isaac Marcadis, MD    561-689-0606      
Principal Investigator: Isaac Marcadis, MD         
United States, Georgia
Emory University Recruiting
Atlanta, Georgia, United States, 30322
Contact: Evan Anderson, MD    404-727-1746      
Principal Investigator: Evan Anderson, MD         
United States, Kansas
Johnson County Clin-Trials Recruiting
Lenexa, Kansas, United States, 66219
Contact: Casey Johnson, MD    913-825-4400      
Principal Investigator: Casey Johnson, MD         
Heartland Research Recruiting
Witchita, Kansas, United States, 67207
Contact: Terry Klein, MD    316-689-6629      
Principal Investigator: Terry Klein, MD         
United States, Kentucky
University of Kentucky Recruiting
Lexington, Kentucky, United States, 40536
Contact: Richard Greenberg, MD    859-323-6327      
Principal Investigator: Richard Greenberg, MD         
Central Kentucky Research Recruiting
Lexington, Kentucky, United States, 40509
Contact: James Borders, MD    859-278-5926 ext 209      
Principal Investigator: James Borders, MD         
United States, Massachusetts
Boston University Recruiting
Boston, Massachusetts, United States, 02218
Contact: Elizabeth Barnett, MD    617-414-3623      
United States, Missouri
Center for Pharmaceutical Research Recruiting
Kansas City, Missouri, United States, 64114
Contact: John Ervin, MD    816-943-0770      
Principal Investigator: John Ervin, MD         
St. Louis University Recruiting
St Louis, Missouri, United States, 63104
Contact: Geoffrey Gorse, MD    314-977-5500      
Principal Investigator: Geoffrey Gorse, MD         
United States, South Carolina
Coastal Carolina Research Recruiting
Mt. Pleasant, South Carolina, United States, 29464
Contact: Cynthia Strout, MD    843-856-3784      
Principal Investigator: Cynthia Strout, MD         
United States, Texas
Research Across America Recruiting
Dallas, Texas, United States, 75234
Contact: Ronald Kapusta, MD    972-241-1222      
United States, Utah
Jean Brown Research Recruiting
Salt Lake City, Utah, United States, 84124
Contact: Stephen Richardson, MD    801-261-2000      
Principal Investigator: Stephen Richardson, MD         
United States, Vermont
University of Vermont Recruiting
Burlington, Vermont, United States, 05405
Contact: Beth Kirkpatrick, MD    802-656-5288      
Principal Investigator: Beth Kirkpatrick, MD         
Australia, Queensland
AUS Trials Pty Ltd Recruiting
Sherwood, Queensland, Australia, 4035
Contact: Carol Bendall    +61 7 3278 5255      
Principal Investigator: Fred De Looze, MD         
Australia, Victoria
Emeritis Research Recruiting
Malvern East, Victoria, Australia, 3145
Contact: Gail Grant    +61 3 9509 6166      
Principal Investigator: Stephen Hall, Prof         
Nucleus Network Recruiting
Melbourne, Victoria, Australia, 3004
Contact: Cameron Johnson    +61 3 9076 8906      
Principal Investigator: Jason Lickliter, MD         
The University of Melbourne Recruiting
Melbourne, Victoria, Australia, 3010
Contact: Marita Kefford    613 8344 9137      
Principal Investigator: Terry Nolan, MD         
Sponsors and Collaborators
PaxVax, Inc.
  More Information

No publications provided

Responsible Party: PaxVax, Inc. Identifier: NCT02100631     History of Changes
Other Study ID Numbers: PXVX-VC-200-005
Study First Received: March 25, 2014
Last Updated: July 10, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Vibrio Infections
Gram-Negative Bacterial Infections
Bacterial Infections processed this record on August 20, 2014